Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Bone Research
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1480847

Decreased sirtuin 1 in type 2 diabetes patients with increased BMD

Provisionally accepted
Yao Xu Yao Xu Tianxiao Hu Tianxiao Hu *Xiujing Wang Xiujing Wang *Ting Wang Ting Wang *Huiling Shen Huiling Shen *Zhenying Zhang Zhenying Zhang *Bojing Zheng Bojing Zheng *Jiaqi Yao Jiaqi Yao *Yanxia Ren Yanxia Ren *Jing Wang Jing Wang *Qingying Tan Qingying Tan *
  • The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China

The final, formatted version of the article will be published soon.

    Sirtuin 1, a class III histone deacetylase, plays a critical role in the pathophysiology of both diabetes mellitus and bone metabolism by promoting osteoblast differentiation and inhibiting osteoclast maturation. However, its exact impact on bone mineral density (BMD) and bone metabolism in type 2 diabetes mellitus (T2DM) remains unclear. This study investigates the relationship between Sirtuin 1 levels, BMD, and bone metabolism in newly diagnosed T2DM patients, specifically examining alterations in Sirtuin 1 levels in those with concomitant osteoporosis or osteopenia. A total of 69 newly diagnosed T2DM patients and 82 control subjects with normal glucose tolerance (NGT) were enrolled. Serum Sirtuin 1 levels and bone turnover markers, including osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), and β-C-terminal telopeptide of type I collagen (β-CTX), were measured using enzyme-linked immunosorbent assay (ELISA). BMD was assessed via dual-energy X-ray absorptiometry (DXA). Comparisons of these parameters were made between the T2DM and NGT groups. T2DM patients were further categorized into a normal BMD group (DMn) and an osteopenia or osteoporosis group (DMo), and differences in Sirtuin 1 levels between these subgroups were analyzed. Risk factors for osteoporosis/osteopenia in T2DM patients were also evaluated. Serum Sirtuin 1 levels

    Keywords: Sirtuin 1, bone mineral density, Bone turnover markers, type 2 diabetes mellitus, bone metabolism

    Received: 14 Aug 2024; Accepted: 10 Dec 2024.

    Copyright: © 2024 Xu, Hu, Wang, Wang, Shen, Zhang, Zheng, Yao, Ren, Wang and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Tianxiao Hu, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Xiujing Wang, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Ting Wang, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Huiling Shen, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Zhenying Zhang, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Bojing Zheng, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Jiaqi Yao, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Yanxia Ren, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Jing Wang, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China
    Qingying Tan, The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.